Ulcerative Colitis

SAN FRANCISCO — Noninvasive monitoring methods, such as enterography and ultrasound, are becoming increasingly recognized as essential tools in the management of pediatric patients with inflammatory bowel disease, according to presenters.

Oral vancomycin therapy resulted in clinical response in nearly half of patients with inflammatory bowel disease associated with primary sclerosing cholangitis, according to a study published in Therapeutic Advances in Gastroenterology.

SAN FRANCISCO — Although Stelara and Entyvio demonstrated similar cardiovascular safety profiles among older patients with inflammatory bowel disease, Stelara was associated with reduced all-cause mortality risk over 3 years, data showed.

In a large cohort of patients with autoimmune diseases, treatment with biologic disease-modifying antirheumatic drugs was associated with reduced incidence of Parkinson’s disease, data show.

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory bowel disease, Lilly reported.

SARS-CoV-2 infection, especially a severe case or without vaccination, significantly increases the long-term risk for developing autoimmune and autoinflammatory connective tissue diseases, according to data published in JAMA Dermatology.

The expansion of safe and effective FDA-approved biosimilars for inflammatory bowel disease set to launch in early 2025 may improve access to care, with the potential to reduce health care costs and revolutionize the treatment landscape.

The FDA has approved the Stelara biosimilar Steqeyma for the treatment of adults and children with plaque psoriasis and psoriatic arthritis and adults with Crohn’s disease and ulcerative colitis, Celltrion announced in a press release.

Baseline concomitant exposure to commonly used medications, such as corticosteroids and 5-aminosalicylates, did not significantly affect clinical and endoscopic outcomes during induction therapy in ulcerative colitis, data analysis showed.

The FDA has approved the Stelara biosimilar Yesintek for indications matching the reference product, with a commercial launch date expected for early 2025, according to a press release from Biocon Biologics.